Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoetharine is a selective, short-acting beta-2 adrenergic receptor agonist and bronchodilator. It acts by stimulating beta-2 adrenergic receptors in bronchial smooth muscle, leading to activation of adenylyl cyclase and increased cyclic AMP (cAMP) levels. This results in relaxation of bronchial smooth muscle, improved airway patency, and relief from symptoms such as wheezing, shortness of breath, coughing, and chest tightness associated with asthma, chronic bronchitis, emphysema, and other obstructive lung diseases. Isoetharine was one of the early selective beta agonists developed after epinephrine and isoprenaline for rapid relief of bronchospasm. It is no longer available in the United States but remains available in some countries including Germany, India, and Japan[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoetharine.